BA Research Update — June 20, 2026 (Updated)
Updated Thesis
The Boeing Company is a leading global aerospace and defense manufacturer operating in commercial airplanes, defense, space, and global services segments. It benefits from a durable competitive moat as one of only two large commercial aircraft OEMs worldwide, supported by high barriers to entry such as certification complexity and extensive supply chains. Despite strong revenue growth of 14% and earnings growth of 89.2% in the most recent quarter, Boeing faces execution challenges reflected in negative operating margins and free cash flow per share of negative $2.46.
The investment grade as of this refresh is C — average business quality. Medium-tier business, high-tier valuation with 45% upside to $322.94 fair value
Key Metrics at a Glance
- Revenue growth: +14.0% year over year
- Net margin: 2.5%
- Forward P/E: 92.0x
- Fair value upside: +45.0% to our estimate of $323
Current price: $222.72
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. The Boeing Company remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full BA research →](/stocks/BA)